Optiscan Imaging Ltd (ASX: OIL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Optiscan Imaging Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Optiscan Imaging Ltd (ASX: OIL)
Latest News
Share Market News
Why the OptiScan (ASX:OIL) share price is rocketing 26% today
Share Market News
Why the Optiscan (ASX:OIL) share price is going gangbusters
Share Market News
Why the OptiScan (ASX:OIL) share price is climbing higher
Share Market News
Optiscan (ASX:OIL) share price flat on FDA update
OIL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Optiscan Imaging Ltd
Optiscan Imaging Ltd is engaged in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications. Its technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions. Its products include InVivage, ViewnVivo, and Customisation. Its geographical segments include Australia, Germany, Norway, China, and the United States.
OIL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 15 Jan 2026 | $0.10 | $0.01 | 11.11% | 9,126 | $0.09 | $0.10 | $0.09 |
| 13 Jan 2026 | $0.09 | $-0.01 | -10.10% | 102,025 | $0.10 | $0.10 | $0.09 |
| 12 Jan 2026 | $0.10 | $0.01 | 10.64% | 182,587 | $0.09 | $0.10 | $0.09 |
| 09 Jan 2026 | $0.09 | $0.00 | 0.00% | 116,156 | $0.09 | $0.09 | $0.09 |
| 08 Jan 2026 | $0.09 | $0.00 | 0.00% | 1,539 | $0.09 | $0.09 | $0.09 |
| 07 Jan 2026 | $0.09 | $0.00 | 0.00% | 154,664 | $0.10 | $0.10 | $0.09 |
| 06 Jan 2026 | $0.10 | $0.00 | 0.00% | 9,054 | $0.10 | $0.10 | $0.10 |
| 05 Jan 2026 | $0.10 | $0.00 | 0.00% | 285,198 | $0.11 | $0.11 | $0.10 |
| 02 Jan 2026 | $0.10 | $0.00 | 0.00% | 52,720 | $0.10 | $0.10 | $0.10 |
| 31 Dec 2025 | $0.10 | $0.00 | 0.00% | 16,953 | $0.10 | $0.10 | $0.10 |
| 30 Dec 2025 | $0.10 | $0.00 | 0.00% | 251 | $0.10 | $0.10 | $0.10 |
| 29 Dec 2025 | $0.10 | $0.00 | 0.00% | 269,727 | $0.11 | $0.11 | $0.10 |
| 24 Dec 2025 | $0.11 | $0.00 | 0.00% | 104,856 | $0.11 | $0.11 | $0.11 |
| 23 Dec 2025 | $0.10 | $0.00 | 0.00% | 94,981 | $0.10 | $0.10 | $0.10 |
| 22 Dec 2025 | $0.11 | $0.00 | 0.00% | 165,768 | $0.11 | $0.11 | $0.11 |
| 19 Dec 2025 | $0.11 | $0.01 | 10.20% | 84,913 | $0.10 | $0.11 | $0.10 |
| 18 Dec 2025 | $0.10 | $-0.01 | -9.52% | 240,260 | $0.10 | $0.10 | $0.10 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 19 Dec 2025 | Karen Borg | Transfer | 210,365 | $17,881 |
Off-market transfer. As per announcement on 29-12-2025
|
| 26 Sep 2025 | Robert Cooke | Buy | 72,500 | $6,101 |
On-market trade.
|
| 23 Sep 2025 | Karen Borg | Issued | 24,929 | $2,118 |
Rights issue.
|
| 23 Sep 2025 | Karen Borg | Transfer | 99,716 | $8,076 |
Off-market transfer. Assuming off market transfer of shares
|
| 23 Sep 2025 | Karen Borg | Transfer | 99,716 | $8,076 |
Off-market transfer. Assuming off market transfer of shares
|
| 23 Sep 2025 | Ronnie (Ron) Song | Issued | 250,000 | $21,250 |
Rights issue.
|
| 23 Sep 2025 | Camile Farah | Issued | 235,294 | $20,000 |
Rights issue.
|
| 21 Mar 2025 | Camile Farah | Buy | 12,984 | $1,555 |
On-market trade.
|
| 17 Mar 2025 | Camile Farah | Buy | 195,385 | $23,474 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Ronnie (Ron) Song | Non-Executive Director | Feb 2021 |
Mr Song had a 25-year business career in Australia before being headhunted in 1999 to assist in expanding a multi-franchise European motor vehicle importership in Singapore. He developed the Singapore Audi importership, Premium Automobiles Pte Ltd, where he was the Managing Director for seven years. Ron was then appointed as operation director to further develop a premier Singaporean wellness company, Fabulous Image Lifestyle. He has established a network of business contacts in many areas of enterprise in Asia and Australia. He has contacts in the health sector in Asia as well as associations with businesses and the financial sector in Australia and Asia of value to Optiscan. He is a member of risk committee.
|
| Mr Robert Cooke | Non-Executive ChairmanNon-Executive Director | Apr 2021 |
Mr Cooke has 40+ year career in the health industry, his experience spans executive leadership of publicly listed and privately owned healthcare companies, and management of private and public hospitals in Australia, Asia and the UK. He is a member of Risk committee.
|
| Ms Karen Borg | Non-Executive Director | Jul 2021 |
Ms Borg has held senior roles in FTSE 100-250 medical device, technology, consumer products and government services organisations. She was the Chief Executive Officer for Catholic Healthcare Ltd and prior to this was the CEO of Healthdirect and the inaugural CEO of Jobs for NSW. She began her career in consumer goods sector and worked for Goodman Fielder, Nestle and Revlon in global business development and marketing. She holds chairmanship of Risk committee.
|
| Professor Camile Farah | Chief Executive OfficerManaging Director | May 2021 |
Dr Farah has over 25 years of experience leading transformational change across medtech, life sciences, and academic healthcare. He holds multiple non-executive and advisory roles within the medtech, life sciences and healthcare sectors. He has held CEO, Board, and C-suite roles in medtech and diagnostic companies, driving commercial strategy, capital raising, global market expansion, and regulatory approvals.
|
| Mr Sean Gardiner | Non-Executive Director | Jun 2022 |
Mr Gardiner worked at Morgan Stanley, where he spent 20 years in equity research across three locations and in seven different roles. He joined the London office, covering European Technology and Conglomerate stocks before, in 2005, moving to lead the EEMEA Telecom Services team. In early 2008, Sean transferred to Dubai to setup and manage the MENA Equity Research team. Sean relocated to Singapore in 2010 to oversee and manage the broader Asian research product as well as roll out ASEAN Real Estate coverage. He is a member of risk committee.
|
| Ms Elissa Hansen | Company Secretary | Feb 2025 |
-
|
| Elissa Hansen | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Peters Investments Pty Ltd | 235,840,699 | 28.23% |
| HSBC Custody Nominees (Australia) Limited | 156,477,921 | 18.73% |
| Ibsen Pty Ltd (Narula Family Set No3 A/C) | 38,500,000 | 4.61% |
| Citicorp Nominees Pty Limited | 38,456,930 | 4.60% |
| Harech Pty Ltd (Porter Super Fund A/C) | 16,659,185 | 1.99% |
| BNP Paribas Noms Pty Ltd | 15,374,184 | 1.84% |
| Mr Chris Graham + Mrs Diane Graham (C & D Graham S/F A/C) | 12,700,000 | 1.52% |
| Dixson Trust Pty Limited | 8,474,270 | 1.01% |
| Camile Farah + Marie Matias (Farah & Matias Family A/C) | 8,000,000 | 0.96% |
| BNP Paribas Noms Pty Ltd Uobkh A/C R'Miers | 7,377,386 | 0.88% |
| Kebin Nominees Pty Ltd | 6,784,479 | 0.81% |
| Mr Kah Chin Lee | 5,088,888 | 0.61% |
| Ibsen Pty Ltd (Ibsen Superfund A/C) | 5,000,000 | 0.60% |
| Mr Christopher John Martin | 4,209,448 | 0.50% |
| Mr Wally Knezevic | 4,134,260 | 0.49% |
| Mr Alfred Joseph Winkelmeier + Mrs Christine Edith Winkelmeier <The Winkelmeier S/F A/C> | 3,710,000 | 0.44% |
| Semblance Pty Ltd (Graeme Mutton Retire S/Fund) | 3,540,000 | 0.42% |
| Sash Pty Ltd (Knezevic Super Fund A/C) (i) | 3,515,741 | 0.42% |
| Mr Jubran William Toak + Mr Melhem William Toak | 3,422,996 | 0.41% |
| Sash Pty Ltd (Knezevic Super Fund A/C) (ii) | 3,422,223 | 0.41% |